RIGI and Immunodeficiency: Considering the pathogenic roles of these new RIG-I activators in the elderly, patients in ICU, patients with organ transplantation, and patients with immune deficiency (48–51), targeting RIG-I could be a therapeutic option for these patients.These activators of RIG-I are summarized in Table 1.